Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911531 · ClinicalTrials.gov registry record
Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops
A clinical trial of Nonimmune Fetal Hydrops and Nonimmune Hydrops in Neonate, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT03911531 is a study of Nonimmune Fetal Hydrops and Nonimmune Hydrops in Neonate that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 55 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03911531, a study of Nonimmune Fetal Hydrops and Nonimmune Hydrops in Neonate, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Brief Summary: Nonimmune hydrops fetalis (NIHF) is a potentially fatal condition characterized by abnormal fluid accumulation in two or more fetal compartments. Numerous etiologies may lead to NIHF, and the underlying cause often remains unclear (1). The current standard of genetic diagnostic testing includes a fetal karyotype and chromosomal microarray (CMA), with an option to pursue single gene testing on amniocytes collected by amniocentesis (2). A large subgroup of the NIHF causes includes single gene disorders that are not diagnosed with the standard genetic workup for hydrops. Currently, nearly 1 in 5 cases of NIHF is defined as idiopathic, meaning there is no identified etiology (2). The investigators believe this is because the causes of NIHF are not completely investigated, specifically single gene disorders. Our research study aims to increase the diagnostic yield by performing whole exome sequencing (WES) and whole genome sequencing (WGS) on prenatal and neonatal NIHF cases when standard genetic testing is negative, identifying known and new genes, thus providing vital information to families regarding the specific diagnosis and risk to future pregnancies. The investigators plan to perform WES as the initial diagnostic test. If WES is negative, then the investigators will proceed to perform WGS.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Whole Exome Sequencing
- DIAGNOSTIC_TEST Whole Genome Sequencing
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911531
The ClinicalTrials.gov registry entry for NCT03911531 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Nonimmune Fetal Hydrops appearing as the primary indexed condition, and to 2 interventions - of which Whole Exome Sequencing is the first listed.
NCT03911531 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03911531 about?
NCT03911531 is a clinical study titled "Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops". Brief Summary: Nonimmune hydrops fetalis (NIHF) is a potentially fatal condition characterized by abnormal fluid accumulation in two or more fetal compartments. Numerous etiologies may lead to NIHF, and the underlying cause often remains unclear (1). The current standard of genetic diagnostic testin...
What is the current status of trial NCT03911531?
This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2019-01-15. Estimated completion is 2028-12-31.
What conditions does trial NCT03911531 study?
This clinical trial studies the following conditions: Nonimmune Fetal Hydrops, Nonimmune Hydrops in Neonate, Genetic Disorders.
What interventions are being tested in trial NCT03911531?
The interventions under investigation include: Whole Exome Sequencing (DIAGNOSTIC_TEST), Whole Genome Sequencing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03911531?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03911531 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.